RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies
A Phase I Dose-finding and Pharmacokinetic Study of RTA 402 (CDDOMe) Administered Orally for 21 Days of a 28-day Cycle in Patients With Advanced Solid Tumors or Lymphoid Malignancies
Sponsor: Biogen
A PHASE1 clinical study on Advanced Solid Tumors and Lymphoid Malignancies, this trial is completed. The trial is conducted by Biogen and has accumulated 9 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Jun 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Jun 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Mar 2024 — Jul 2024 [monthly]
Completed PHASE1
-
Nov 2023 — Mar 2024 [monthly]
Completed PHASE1
▶ Show 4 earlier versions
-
Jan 2021 — Nov 2023 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1
First recorded
Apr 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Biogen
For direct contact, visit the study record on ClinicalTrials.gov .